Not found

Helen Yicheng Wang,

Associate Research Professor of Inflammation and Epigenetics, Institute for Academic Medicine
Associate Research Member, Research Institute
Houston Methodist


Ms. Wang began her research training at the University of Georgia and Stanford University School of Medicine in the fields of molecular biology and biochemistry. In 1994, she joined the American Red-Cross Laboratory, and later moved to the National Institute of Health as a biologist. During that time, she became interested in immunology, focusing on cytokine biology, signaling transduction, and T-cell biology in autoimmune diseases.

Ms. Wang was appointed assistant professor at Baylor College of Medicine in 2007, and assistant member at The Methodist Hospital Research Institute in 2012. At Baylor College of Medicine, Ms. Wang identified T-cell recognized tumor antigens that can be engineered for the development of novel cancer vaccines. Dr. Wang’s research at Baylor College of Medicine provided the first evidence that antigen-specific regulatory T (Treg) cells dampen antitumor immunity elicited by cancer vaccines. She later showed that this suppressive function of Treg cells can be reversed by activating innate immune receptors.

Ms. Wang now directs a T Cell Biology laboratory that is studying a set of critical immune targets associated with cancer, obesity and neurodegenerative diseases and subsets of T cells. The goal of these studies is to develop novel vaccines or drugs for the prevention and treatment of cancer, obesity and neurodegenerative diseases.

Description of Research

Ms. Wang’s team studies the role of T cells in antigen recognition and immune regulation. Her projects include identifying mechanisms of cytokine signaling in immune cells, tumor antigen discovery, and defining mechanisms of regulatory T cell function and innate immune signaling. A critical goal of her research is to identify antigens that are recognized by various T cells, including Th1, Th17 and Treg cells. This knowledge is essential for understanding how the host immune system responds to cancer, obesity and neurodegenerative diseases, and provides important therapeutic targets for development of effective vaccines against cancer and neurodegenerative diseases.

Ms. Wang also works on understanding innate immune signaling pathways, in particular Toll-like receptor (TLR8) signaling in the reversal of regulatory T cell suppressive functions. Negative regulators play a critical role in controlling immune balance and inflammation, which has been linked to the development of cancer and many other diseases. Her team is therefore investigating how to improve immune responses by reducing the levels of these negative regulators in immune cells. These research findings have the potential to translate into novel therapeutics for diseases such as cancer, obesity and inflammation-associated diseases like ALS.

Areas Of Expertise

Cancer immunology Cancer immunotherapy Innate immune signaling Antigen presentation Epigenetics Tumor Antigen Discovery Engineering T cell Therapy IEpigenetics

JMJD3 as an epigenetic regulator in development and disease
Burchfield, JS, Li, Q, Wang, HY & Wang, RF 2015, International Journal of Biochemistry and Cell Biology, vol 67, 4662, pp. 148-157. DOI:

Identification of DRG-1 as a melanoma-associated antigen recognized by CD4<sup>+</sup> Th1 cells
Kiniwa, Y, Li, J, Wang, M, Sun, C, Lee, JE, Wang, RF & Wang, HY 2015, PLoS ONE, vol 10, no. 5, e0124094. DOI:

Current advances in T-cell-based cancer immunotherapy
Wang, M, Yin, B, Wang, HY & Wang, RF 2014, Immunotherapy, vol 6, no. 12, pp. 1265-1278. DOI:

Mechanisms and pathways of innate immune activation and regulation in health and cancer
Cui, J, Chen, Y, Wang, HY & Wang, RF 2014, Human Vaccines and Immunotherapeutics, vol 10, no. 11, pp. 3270-3285. DOI:

Critical role of histone demethylase Jmjd3 in the regulation of CD4 + T-cell differentiation
Li, Q, Zou, J, Wang, M, Ding, X, Chepelev, I, Zhou, X, Zhao, W, Wei, G, Cui, J, Zhao, K, Wang, HY & Wang, RF 2014, Nature Communications, vol 5, 5780. DOI:

The future potential for cocaine vaccines
Orson, FM, Wang, R, Brimijoin, S, Kinsey, BM, Singh, RAK, Ramakrishnan, M, Wang, HY & Kosten, TR 2014, Expert Opinion on Biological Therapy, vol 14, no. 9, pp. 1271-1283. DOI:

USP3 inhibits type i interferon signaling by deubiquitinating RIG-I-like receptors
Cui, J, Song, Y, Li, Y, Zhu, Q, Tan, P, Qin, Y, Wang, HY & Wang, RF 2014, Cell Research, vol 24, no. 4, pp. 400-416. DOI:

HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer
Sonpavde, G, Wang, M, Peterson, LE, Wang, HY, Joe, T, Mims, MP, Kadmon, D, Ittmann, MM, Wheeler, TM, Gee, AP, Wang, RF & Hayes, TG 2014, Investigational New Drugs, vol 32, no. 2, pp. 235-242. DOI:

Stage-Dependent and Locus-Specific Role of Histone Demethylase Jumonji D3 (JMJD3) in the Embryonic Stages of Lung Development
Li, Q, Wang, HY, Chepelev, I, Zhu, Q, Wei, G, Zhao, K & Wang, RF 2014, PLoS Genetics, vol 10, no. 7, e1004524. DOI:

Cell type-specific function of TAK1 in innate immune signaling
Ajibade, AA, Wang, HY & Wang, RF 2013, Trends in Immunology, vol 34, no. 7, pp. 307-316. DOI:

Class II major histocompatibility complex plays an essential role in obesity-induced adipose inflammation
Deng, T, Lyon, CJ, Minze, LJ, Lin, J, Zou, J, Liu, JZ, Ren, Y, Yin, Z, Hamilton, DJ, Reardon, PR, Sherman, V, Wang, HY, Phillips, KJ, Webb, P, Wong, STC, Wang, RF & Hsueh, WA 2013, Cell Metabolism, vol 17, no. 3, pp. 411-422. DOI:

Jmjd3 inhibits reprogramming by upregulating expression of INK4a/Arf and targeting PHF20 for ubiquitination
Zhao, W, Li, Q, Ayers, S, Gu, Y, Shi, Z, Zhu, Q, Chen, Y, Wang, HY & Wang, RF 2013, Cell, vol 152, no. 5, pp. 1037-1050. DOI:

Identification of Special AT-Rich Sequence Binding Protein 1 as a Novel Tumor Antigen Recognized by CD8+ T Cells: Implication for Cancer Immunotherapy
Wang, M, Yin, B, Matsueda, S, Deng, L, Li, Y, Zhao, W, Zou, J, Li, Q, Loo, C, Wang, RF & Wang, HY 2013, PLoS ONE, vol 8, no. 2, e56730. DOI:

Identification of Prostate-Specific G-Protein Coupled Receptor as a Tumor Antigen Recognized by CD8+ T Cells for Cancer Immunotherapy
Matsueda, S, Wang, M, Weng, J, Li, Y, Yin, B, Zou, J, Li, Q, Zhao, W, Peng, W, Legras, X, Loo, C, Wang, RF & Wang, HY 2012, PLoS ONE, vol 7, no. 9, e45756. DOI:

Enhanced TLR-induced NF-?B signaling and type I interferon responses in NLRC5 deficient mice
Tong, Y, Cui, J, Li, Q, Zou, J, Wang, HY & Wang, RF 2012, Cell Research, vol 22, no. 5, pp. 822-835. DOI:

NLRP4 negatively regulates type I interferon signaling by targeting the kinase TBK1 for degradation via the ubiquitin ligase DTX4
Cui, J, Li, Y, Zhu, L, Liu, D, Songyang, Z, Wang, HY & Wang, RF 2012, Nature Immunology, vol 13, no. 4, pp. 387-395. DOI:

Enhancing Cancer Immunotherapy by Intracellular Delivery of Cell-Penetrating Peptides and Stimulation of Pattern-Recognition Receptor Signaling
Wang, HY & Wang, RF 2012, Advances in Immunology, vol 114, pp. 151-176. DOI:

TAK1 Negatively Regulates NF-?B and p38 MAP Kinase Activation in Gr-1 +CD11b + Neutrophils
Alagbala Ajibade, A, Wang, Q, Cui, J, Zou, J, Xia, X, Wang, M, Tong, Y, Hui, W, Liu, D, Su, B, Wang, HY & Wang, RF 2012, Immunity, vol 36, no. 1, pp. 153. DOI:

TAK1 Negatively Regulates NF-?B and p38 MAP Kinase Activation in Gr-1 +CD11b + Neutrophils
Alagbala Ajibade, A, Wang, Q, Cui, J, Zou, J, Xia, X, Wang, M, Tong, Y, Hui, W, Liu, D, Su, B, Wang, HY & Wang, RF 2012, Immunity, vol 36, no. 1, pp. 43-54. DOI:

Tumor antigens and immune regulation in cancer immunotherapy
Wang, RF & Wang, HY 2012, . in Innate Immune Regulation and Cancer Immunotherapy. Springer New York, pp. 371-390. DOI: